Report Back From ASCO 2023: What’s the Latest News in MBC Research?

Report Back From ASCO 2023: What’s the Latest News in MBC Research?

Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.

Read More
2022 in Review: Best in MBC with Dr. Erika Hamilton

2022 in Review: Best in MBC with Dr. Erika Hamilton

Welcome to the first Road to A Cure episode of Season 6. Our guest is the incomparable Dr. Erika Hamilton, a breast oncologist and researcher who, as she says herself, doesn’t shy away from difficult questions. In this episode, we get a review—subtype by subtype—of the biggest news over the past 15 months. Of course, we also talk about what is on the horizon in MBC.

Read More
ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

ASCO 2022: When the Dust Settles, Will ADCs Change MBC?

While HER2-Low and DESTINY-Breast04 garnered most of the headlines from the ASCO 2022 in June, it was not the only reason for optimism. Our MBC Life takes a deeper dive with Dr. Stephanie Graff and Dr. Hope Rugo in this first episode of our two-part series.

Read More
Report Back from ASCO 2022: What’s the Latest in MBC Research?

Report Back from ASCO 2022: What’s the Latest in MBC Research?

The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO

Read More
Road to a Cure - ADC & SARM

Road to a Cure - ADC & SARM

How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.

Read More